Bone marrow transplantation in the United Kingdom - past, present and future.
allogeneic
autologous
bone marrow transplantation
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
25
08
2020
accepted:
02
09
2020
entrez:
15
11
2020
pubmed:
16
11
2020
medline:
16
6
2021
Statut:
ppublish
Résumé
Bone marrow transplantation (BMT) has evolved over the last 60 years from a pioneering treatment fraught with unknown factors and complications to a widely practiced standard of care that has saved the lives of countless individuals with malignant and non-malignant conditions. Over this period, transplanters in the UK have made a significant international contribution to the field through cutting edge clinical and laboratory research. Today, stem cell transplantation in the UK continues to advance through rigorous and innovative clinical trials which focus on improving outcome by reducing transplant toxicity and the risk of disease relapse. In this review, we start with a personal view of the early years of BMT in the UK, document the many seminal accomplishments in the field of BMT which took place in the UK, and end with a look towards the future of BMT, in the UK and worldwide.
Types de publication
Historical Article
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
612-616Informations de copyright
© 2020 British Society for Haematology and John Wiley & Sons Ltd.
Références
Pegg DE, Humble JG, Newton KA. The clinical application of bone marrow grafting. Brit J Cancer. 1962;16:417-35.
Westbury G. Sir Stanford Cade - Pioneer oncologist. Int J Radiation Oncol Biol Phys. 1978;4:1-2.
Yamamura M, Newton RCF, James DCO, Humble JG, Butler LJ, Hobbs JR. Uncomplicated HL-A matched sibling bone marrow graft for combined immune deficiency. Br Med J. 1972;2:265-9.
Hobbs JR, Hugh-Jones K, Barrett AJ, Byrom N, Chambers D, Henry K, et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet. 1981;2:709-12.
Powles RL, Morgenstern G, Clink HM, Hedley D, Bandini G, Lumley H, et al. The place of bone-marrow transplantation in acute myelogenous leukaemia. Lancet. 1980;1:1047-50.
Daley GQ, Goldman JM. Autologous transplant for CML revisited. Exp Hematol. 1993;21:734-7.
Barrett AJ, Kendra JR, Lucas CF, Joss DV, Joshi R, Pendharkar P, et al. Cyclosporin A as prophylaxis against graft-versus-host disease in 36 patients. Br Med J (Clin Res Ed). 1982;285:162-6.
Waldmann H, Hale G. CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci. 2005;360:1707-11.
Oakhill A, Pamphilon DH, Potter MN, Steward CG, Goodman S, Green A, et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol. 1996;94:574-8.
McCarthy DM, Goldman JM. Transfusion of circulating stem cells. Crit Rev Clin Lab Sci. 1984;20:1-24.
Russell Nh, Hunter A, Rogers S, Hanley J, Anderson D. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet. 1993;341(8858):1482.
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-62.
Dazzi F, Szydlo RM, Craddock C, Cross NCP, Kaeda J, Chase A, et al. Comparison of single-dose and escalating- dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 2000;95:67-71.
Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993;82:1929-36.
Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2000;96:2712-6.
Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, et al. In vivo Campath-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419-25.
Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation. Blood. 2002;99:1071-8.
Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23:9387-93.
McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2:822-4.
Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:874-85.
Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide before and after Autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized Phase III Myeloma XI trial. Haematologica. 2020, 247130. [epub ahead of print].
Gribben JG, Goldstone AH, Linch DC, Taghipour G, McMillan AK, Souhami RL, et al. Effectiveness of high dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still sensitive to conventional dose therapy. J Clin Oncol. 1989;7:1621-9.
Souhami RL, Harper PG, Linch D, Trask C, Goldstone AH, Tobias J, et al. High-dose cyclophosphamide with autologous marrow transplantation as initial treatment of small cell carcinoma of the bronchus. Cancer Chemother Pharmacol. 1982;8:31-4.
Linch DC, Goldstone AH, McMillan A, Chopra R, Vaughan Hudson G, Winfield D, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341:1051-4.
Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z, et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 2017;1(27):2742-55.
Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP, et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood. 2007;110:4614-7.
Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S, et al. Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial. Biol Blood Marrow Transplant. 2016;22:385-90.